Scotia is now well on the way to selecting those elements of its R&D pipeline which it will develop in-house, and which it will license out, as part of its ongoing restructuring of the business. Research costs for the six months to June 30 increased 14% to L8.4 million ($13 million), compared to the year-earlier period.
Chief executive David Horrobin said at the firm's interim results meeting (see also page 4), that Scotia will now concentrate on four main areas, namely diabetology, oncology, benign breast disease and dermatology. And in future, Scotia intends to retain much more strategic control over its core brands. The programs which have been selected for out-licensing are shown in the table below:
Candidates For Out-Licensing* Product Indication Status -------------------------------------------------------------------------- EF5 + related rheumatology Trial ends SC compounds 1Q97 -------------------------------------------------------------------------- EF12 + related cardiology Trial ends SC compounds 1Q98 -------------------------------------------------------------------------- SC109 asthma - -------------------------------------------------------------------------- SC106 inflammation - -------------------------------------------------------------------------- SC108 cardiology - -------------------------------------------------------------------------- SC116 osteoporosis - -------------------------------------------------------------------------- * Out-license all products for Latin America, Eastern Europe/CIS
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze